Eli Lilly and Company (LLY)
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday.
Lilly's Zepbound Beats Novo's Wegovy in Weight-Loss Drug Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S's Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks.
Eli Lilly Touts Upbeat Weight-Loss Drug Results
The weight-loss drug market is about to get even more crowded.
Eli Lilly's stock rises as Zepbound weight-loss drug achieves a key goal
Zepbound helped patients lose more weight than a major rival in a head-to-head trial.
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
The magic isn't over for Eli Lilly (LLY 1.69%). Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings suggest Zepbound may be a superior treatment for weight loss, helping patients with obesity or who are overweight lose 20.2% of their body weight on average after 72 weeks.
Why Is Lilly (LLY) Down 5% Since Last Earnings Report?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Eli Lilly investors have suffered an unexpected bear market as recent headwinds buffeted the stock. Notwithstanding near-term execution challenges, Lilly's weight loss drugs are gaining more share. Potential policy changes under the Biden administration could benefit Lilly, but they are unlikely to be resolved before Trump takes office.
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
Eli Lilly (LLY -0.14%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion. But in recent weeks, its share price has been falling.
